Targeting PD1 and PDL1 in lung cancer treatment: Where are we now?doi:10.1016/j.jtho.2015.12.012HerbstYale Cancer Center, New Haven, CT;Roy S.Yale Cancer Center, New Haven, CT;elsevierJournal of Thoracic Oncology
学校代码10459学号或申请号201322453696密级公开专业硕士学位论文晚期肺腺癌患者组织中p53、PD-L1表达与预后的关系作者姓名:***师姓名:***授专业学位名称:内科学(..
CONCLUSIONS: NSCLC patients with positive PD-L1 expression exhibited poor OS. The PD-L1 expression was higher in tumors with poor differentiation. [13]Wang A, Wang H Y, Liu Y, et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis[J]....
参考文献 1 Alessandro Di Federico, Andrea De Giglio, Claudia Parisi, et al. PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the ...
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer.在KEYNOTE-024研究中,对于肿瘤细胞PD-L1表达≥50%,且无EGFR或ALK敏感突变的晚期非小细胞肺癌患者,相比于化疗,一线应用Pembrolizumab可以延长患者的生存期。基于此研究,FDA批准Pembro用于一线治疗PD-L1表达水平≥50%且没有EGFR或ALK...
Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer:A real-world,multicenter,r... Objective:Atezolizumab along with chemotherapy has prolonged the survival of patients with extensive-stage small-cell lung cancer(ES-SCLC)worldwid...
Immunology-based therapies are emerging as an effective cancer treatment, using the body's immune system to target tumors. Immune checkpoints, which regulate immune responses to prevent tissue damage and autoimmunity, are often exploited by cancer cells to avoid destruction. The discovery of checkpoint...
Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC) In 33 heavily pretreated NSCLC EGFR wild-type (EGFRwt) patients the combination of AFM24 and atezolizumab shows an overall response rate (ORR) of 21% (6 confirmed responses, ...
positivecutoffminimizestheconcern §%positivityofinterstitialcellsaddsanadditional levelofcomplexity §PDL1expressiontrivialifnoeffectorcellspresent §PDL1expressionnotusefultoexcludepatients: responseratesaround10%inPDL1negative tumors,thusmakingtheseagentsaseffectiveas ...
采用肿瘤细胞阳性比例分数(tumor cell proportion score,TPS)及联合阳性分数(combined positive score,CPS)指标分析免疫组织化学染色结果评价肿瘤组织的PD-L1表达情况。结果:68Ga-DOTA-PDL1P的标记率及放射化学纯度均大于99%,并在磷酸...